We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Plasma NT-ProBNP Levels Predict Severity of Enterovirus-71 Infection

By LabMedica International staff writers
Posted on 08 Dec 2016
Print article
Image: The XE-2100 automated hematological parameters analyzer (Photo courtesy of Sysmex).
Image: The XE-2100 automated hematological parameters analyzer (Photo courtesy of Sysmex).
Hand, foot, and mouth disease (HFMD) is caused by a variety of human enteroviruses, mainly by enterovirus 71 (EV71) and coxsackievirus A16 (CA16), and is characterized by fever and vesicular exanthema on the hands, feet, and mouth.

Brain-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are released in equimolar amounts from the myocardium. Their levels increase in response to hemodynamic stress, and they have an established role in cardiovascular (vasodilation) and renal (natriuresis) physiology, conferring protection against fluid overload and hypertension.

Scientists at the Hunan Children's Hospital (Changsha, China) enrolled between January 2012 and December 2013, 282 patients from pediatric intensive care unit patients with HFMD, 183 (64.89%) were male and the median age of the cohort was 21 months. Cases were recorded as having severe HFMD if they were found to have the more serious complications including encephalitis, meningitis, acute flaccid paralysis, and cardiorespiratory failure, or died.

Venous blood sample for the detection of NT-proBNP was collected during the first hour of hospital admission and was stored immediately at −70 °C. The samples were centrifuged at 3,000 rpm for 20 minutes and analyzed using an electrochemiluminescence immunoassay (Elecsys NT-proBNP; bioMérieux, Lyons, France). The clinical caregivers were blinded to the NT-proBNP values in order to avoid changes to the clinical interventions based on the results. The red blood cell count (RBC), hemoglobin level (Hb), white blood cell (WBC) count, and neutrophil count (Neu) were determined using a Sysmex XE-2100 Automated Hematological Parameters Analyzer (Sysmex Corporation, Kobe, Japan).

The scientists found that NT-proBNP levels were significantly higher in patients with elevated blood glucose of greater than 7.8 mmol/L and increased white blood cell counts of greater than 14 × 109/L. HFMD patients who had no complications had significantly lower NT-proBNP values than patients who died or had complications. The team was able to discriminate between patients with and without brainstem encephalitis, pulmonary edema, pulmonary hemorrhage, circulatory failure, and death, respectively, using NT-proBNP. An NT-proBNP cut-off value of equal to or greater than 1,300 pg/mL demonstrated a high sensitivity of 85% and specificity of 93.5% for predicting death in critical HFMD patients. Children with severe EV71-associated HFMD and NT-proBNP measurements of greater than 1,300 pg/mL had significantly worse overall survival compared to those with levels less than 1,300 pg/mL.

The authors concluded that with the WBC count and blood glucose level, the NT-proBNP level can reflect the severity of EV71-associated HFMD, and NT-proBNP appears to be a better biomarker than the WBC count or hyperglycemia to discriminate severe HFMD patients with or without severe complications. NT-proBNP levels may be able to predict complications or mortality in children with severe EV71-associated HFMD disease in the intensive care unit. The study was published on November 3, 2016, in the International Journal of Infectious Diseases.

Related Links:
Hunan Children's Hospital
bioMérieux
Sysmex
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.